$DAWN News
Last published 6mo ago
- 6mo agoDAWNServier completes the acquisition of Day One BiopharmaceuticalsPR NewswireServier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to ...
- 6mo agoDAWNServier completes the acquisition of Day One BiopharmaceuticalsPR NewswireServier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to ...
- 7mo agoONCYGILDENGNTCRX+1Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of CarePR NewswireUSANewsGroup.com News Commentary — The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by...
- 8mo agoDAWNServier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolioPR NewswireServier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One"), ...
- 8mo agoDAWNServier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolioGlobeNewswireAcquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of
- 8mo agoDAWNDay One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue GuidanceGlobeNewswireOJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with
- 9mo agoDAWNDay One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026GlobeNewswireBRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for
- 10mo agoDAWNDay One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue GuidanceGlobeNewswirePreliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and
- 10mo agoDAWNMRSNDay One Completes Acquisition of Mersana TherapeuticsGlobeNewswireBRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of
- 11mo agoDAWNDay One to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted
- 11mo agoDAWNDay One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual MeetingGlobeNewswireUpdated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least
- 11mo agoDAWNDay One to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted
- 12mo agoDAWNDay One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening DiseasesGlobeNewswireAcquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma
- 1y agoDAWNDay One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual MeetingGlobeNewswireThree-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval data to also be
- 1y agoDAWNDay One Reports Third Quarter 2025 Financial Results and Corporate ProgressGlobeNewswireCommercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-year FIREFLY-1 data
- 1y agoDAWNDay One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025GlobeNewswireBRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for
- 1y agoDAWNDay One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoDAWNDay One Reports Second Quarter 2025 Financial Results and Corporate ProgressGlobeNewswireOJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter
- 1y agoDAWNDay One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025GlobeNewswireBRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for
- 1y agoDAWNDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentGlobeNewswireDr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation
- 1y agoDAWNDay One Reports First Quarter 2025 Financial Results and Corporate ProgressGlobeNewswireOJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash,
- 1y agoDAWNDay One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025GlobeNewswireBRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for
- 1y agoDAWNDay One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate ProgressGlobeNewswireAchieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and
- 1y agoDAWNDay One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025GlobeNewswireBRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for
- 1y agoDAWNDay One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate PrioritiesGlobeNewswirePreliminary 2024 OJEMDA™ (tovorafenib) net product revenue of approximately $57.2 million (unaudited) First dose cohort cleared in Phase 1a/b clinical trial of DAY301 (PTK7-targeted ADC) Ended 2024 with
- 1y agoDAWNDay One to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for
- 1y agoDAWNDay One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & DevelopmentGlobeNewswireDr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day
- 1y agoDAWNDay One to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted
- 2y agoDAWNDay One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoDAWNDay One Reports Third Quarter 2024 Financial Results and Corporate ProgressGlobeNewswireAchieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today,
- 2y agoDAWNDay One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024GlobeNewswireBRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for
- 2y agoDAWNDay One Reports Second Quarter 2024 Financial Results and Corporate ProgressGlobeNewswireAchieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7
- 2y agoDAWNDay One Announces Oversubscribed $175.0 Million Private PlacementGlobeNewswireBRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and commercializing
- 2y agoDAWNDay One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric CancersGlobeNewswireDay One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of adult and pediatric
- 2y agoDAWNDay One Announces Sale of Priority Review Voucher for $108 MillionGlobeNewswireBRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and commercializing
- 2y agoDAWNDay One Reports First Quarter 2024 Financial Results and Corporate ProgressGlobeNewswireOJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE, Calif.,
- 2y agoDAWNDay One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain TumorGlobeNewswireFirst and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate (ORR) of 51%
- 2y agoDAWNDay One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate ProgressGlobeNewswirePDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023 with $366.3 million
- 2y agoDAWNDay One Announces Two New Appointments to Board of DirectorsGlobeNewswireBRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted
- 2y agoDAWNDay One to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted
- 2y agoDAWNDay One Announces Tovorafenib FIREFLY-1 Data Published in Nature MedicineGlobeNewswireBRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted
- 2y agoDAWNDay One to Participate in the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted
- 3y agoDAWNDay One Reports Third Quarter 2023 Financial Results and Corporate ProgressGlobeNewswireNDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals
- 3y agoDAWNDay One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)GlobeNewswireBRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted
- 3y agoDAWNDay One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)GlobeNewswireOverall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision
- 3y agoDAWNDay One Announces VRK1 License Agreement and Research Collaboration with Sprint BioscienceGlobeNewswireDay One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One's portfolio of targeted therapies
- 3y agoDAWNDay One Reports Second Quarter 2023 Financial Results and Corporate ProgressGlobeNewswireResults from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG) evaluable patients
- 3y agoDAWNDay One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireBRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people
- 3y agoDAWNKZIANVSKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMAPR NewswireSYDNEY, June 8, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncology-focused drug development company, is pleased to announce that it is supporting the University of Sydney on a
- 3y agoDAWNDay One Announces Pricing of Public Offering of Common StockGlobeNewswireBRISBANE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people